Navigation Links
Mens Sexual Prowess Not Affected by Prostate Cancer Drug

Men worried about taking finasteride, a drug proven effective in preventing prostate cancer, just because it might effect their performance in the bedroom, can now put their fears to rest, thanks to a new study.

The study, by researchers from the Southwest Oncology Group, found that though the drug does cause a drop in sexual function, the effects diminish over the course of time.

As a part of their study, the researchers surveyed more than 17,000 men 55 and older for seven years, and found that though men given finasteride reported on average more dysfunction than did men given a placebo, the small effect diminished over the seven years.

The study was led by Carol Moinpour, Ph.D., of the Fred Hutchison Cancer Research Center in Seattle.

The study grew out of the Prostate Cancer Prevention Trial, a large double-blind National Cancer Institute-funded study which found that finasteride, a drug which curbs the proliferation of prostate gland cells, is effective at preventing prostate cancer in men age 55 and older.

The 2003 results of that trial, conducted by the Southwest Oncology Group in more than 18,000 men, showed that finasteride could reduce a mans chances of getting prostate cancer by almost 25 percent.

In earlier studies, some men taking finasteride reported decreased libido, impotence and other signs of diminished sexual function. But researchers conducting the new study reported that the previous studies were studies were short-term and didnt try to assess the effects of age and other health factors, as well as individual variation.

The study authors used two surveys, a widely used Sexual Problems Scale and another questionnaire which they created, the Sexual Activity Scale. They also gathered other data to take into account other health factors that affect sexual function, such as age, medical conditions and smoking status. They surveyed the subjects three times in the first year and then annually for seven years.

Was this average decrease (in sexual function) an important difference? We concluded it was not, Moinpour said, adding that there were much larger differences due simply to individual variation among men in the trial.

The study suggests that finasteride will cause little or no sexual dysfunction for most men who decide to take it, conclude the authors.


'"/>




Related medicine news :

1. Sexual abuse affect health for a lifetime
2. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
3. Incidence Of Sexually Transmitted Diseases Among Gay Men On The Rise
4. Testosterone Patches Found To Increase Sexual Desire In Menopausal Women
5. Condom Vending Machines Increasing Sexual Assaults On Women
6. Sexually Abused Girls Develop Eating Disorders
7. Gynaecologist Faces Stiff Prison Sentence On Counts Of Sexual Abuse
8. New Sexual Misconduct Rule Against Doctors In The US
9. Historic Increase In Incidence Of Sexually Transmitted Diseases In Scotland
10. Youth Becoming Sexually Active At A Younger Age
11. Epilepsy Medicine May Result In Sexual Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Horizon Blue ... affirmed the company’s credit rating of “A” and its outlook as “stable.” At the ... capital reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... . These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on ... or disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology: